Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3909 DDI Study with Itraconazole and Rifampicin
NCT06165822Phase 1Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TQB3909 in cancer (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Time to Reach Maximum Observed Plasma Concentration at 72 hours, Maximum Plasma Concentration at 72 hours and 1 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
TQB3909
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06165822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06165822.